Early Communication about an Ongoing Safety Review Orlistat (marketed as Alli and Xenical)
This is a discussion on Early Communication about an Ongoing Safety Review Orlistat (marketed as Alli and Xenical) within the FDA News forum, part of the Industry News and Updates category; FDA is reviewing new safety information regarding reports of liver-related adverse events in patients taking orlistat. Orlistat is marketed ...
|
|||||||
| Register | Help | Members List | Mark Forums Read |
08-24-2009, 03:58 PM
|
|||
|
|||
Early Communication about an Ongoing Safety Review Orlistat (marketed as Alli and Xenical)
FDA is reviewing new safety information regarding reports of liver-related adverse events in patients taking orlistat. Orlistat is marketed in the United States as a prescription product, Xenical, and as an over-the-counter (OTC) product, Alli.
More... 
|
 |
«
Previous Thread
|
Next Thread
»
| Thread Tools | |
| Display Modes | |
Linear Mode
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| Early Communication about an Ongoing Safety Review of Omalizumab (marketed as Xolair) | industry_news | FDA News | 0 | 07-16-2009 03:39 PM |
| FDA issues an Early Communication about an Ongoing Safety Review of clopidogrel bisulfate (marketed as Plavix) | industry_news | FDA News | 0 | 01-26-2009 01:09 PM |
| Follow-up to the January 25, 2008 Early Communication about an Ongoing Data Review for Ezetimibe/Simvastatin (marketed a | industry_news | FDA News | 0 | 01-08-2009 04:32 PM |
| FDA issues an updated Early Communication about an Ongoing Safety Review of Tiotropium (marketed as Spiriva HandiHaler). | industry_news | FDA News | 0 | 10-07-2008 11:37 AM |
| FDA issues an Early Communication About an Ongoing Safety Review of Tumor Necrosis Factor (TNF) Blockers (marketed as Re | industry_news | FDA News | 0 | 06-07-2008 07:30 PM |
© 2008 DrugManagementForum™ powered by |
 |